logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10314834 B1

PDFFull Text
Date of Patent:
Jun. 11, 2019

Filed:

Sep. 09, 2016

Therapeutic agent or treatment method for philadelphia chromosome-positive (ph+) acute lymphocytic leukemia (all) having ikzf1 mutation

Applicants:

University of Yamanashi, Yamanashi, JP;

Tokai University Educational System, Tokyo, JP;

Inventors:

Kanji Sugita, Yamanashi, JP;

Kiyoshi Ando, Kanagawa, JP;

Assignees:

UNIVERSITY OF YAMANASHI, Yamanashi, JP;

TOKAI UNIVERSITY EDUCATIONAL SYSTEM, Tokyo, JP;

Attorney:

Maier & Maier, PLLC

Primary Examiner:

Rei Tsang Shiao

Int. Cl.
CPC ...
A61K 31/454 (2006.01); A61K 45/00 (2006.01); A61K 31/122 (2006.01); A61K 31/167 (2006.01); A61K 31/404 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/496 (2006.01); A61K 31/502 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/553 (2006.01);
U.S. Cl.
CPC ...
A61K 31/454 (2013.01); A61K 31/122 (2013.01); A61K 31/167 (2013.01); A61K 31/404 (2013.01); A61K 31/437 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/496 (2013.01); A61K 31/502 (2013.01); A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61K 31/517 (2013.01); A61K 31/553 (2013.01); A61K 45/00 (2013.01);
Abstract

According to the present invention, there is provided a pharmaceutical composition for treating Philadelphia chromosome positive lymphocytic leukemia, including a thalidomide derivative and BCR-ABL tyrosine kinase inhibitor. According to the present invention there is also provided a method of treating Philadelphia chromosome positive lymphocytic leukemia, including administering a thalidomide derivative and a BCR-ABL tyrosine kinase inhibitor to a patient suffering from Philadelphia chromosome positive lymphocytic leukemia.

Find Patent Forward Citations

Sugita, Kanji. (2019). Therapeutic agent or treatment method for philadelphia chromosome-positive (ph+) acute lymphocytic leukemia (all) having ikzf1 mutation (U.S. Patent No. 10314834). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10314834

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…